Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice
Open Access
- 1 November 2000
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 11 (11), 1437-1443
- https://doi.org/10.1023/a:1026592025862
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG)European Journal of Gastroenterology & Hepatology, 1999
- Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid SyndromeJournal of Clinical Oncology, 1999
- Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)British Journal of Cancer, 1999
- Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumoursEuropean Journal of Cancer, 1996
- Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.Gut, 1996
- Neuroendocrine gastrointestinal tumoursAnnals of Oncology, 1996
- The Human Carcinoid Cell Line, BONAnnals of the New York Academy of Sciences, 1994
- Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- Diagnosis and Treatment of a Carcinoid Tumor Using lodine-131 Meta-iodobenzylguanidineClinical Nuclear Medicine, 1986
- SCINTIGRAPHIC IMAGING OF CARCINOID TUMOURS WITH 131I-METAIODOBENZYLGUANIDINEThe Lancet, 1984